Clinical Trials Browser

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT07181681 2026-04-15

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Phase 1 Recruiting

63 enrolled

Other solid neoplasm

Solid Tumors

NCT07226349 2026-04-15

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

105 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07362888 2026-04-15

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

180 enrolled

Other solid neoplasm

Solid Tumors (Phase 1)

NCT07395258 2026-04-15

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Recruiting

60 enrolled

Other solid neoplasm

Solid Tumors

NCT05155332 2026-04-14

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Recruiting

190 enrolled

Other solid neoplasm

Solid Tumors

NCT05430373 2026-04-14

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Phase 1 Recruiting

31 enrolled

Other solid neoplasm

Solid Tumors, Adult

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06679634 2026-04-14

Retinoblastoma Phase II Expanded Access Clinical Trial

Phase 2 Recruiting

30 enrolled

Other solid neoplasm

Retinoblastoma

NCT06718621 2026-04-14

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

22 enrolled

Other solid neoplasm

Solid Tumor

NCT06143774 2026-04-13

Study of TRX-920 for Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06198010 2026-04-13

ASCENT

Phase NA Recruiting

660 enrolled

Other solid neoplasm

Hematopoietic and Lymphoid System Neoplasm

NCT06352359 2026-04-13

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Phase 1 Recruiting

72 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

Clinical Trials

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

TLN-372 in Advanced KRAS Mutant Solid Tumors

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

A Study of BGM-2121 in Patients With Advanced Solid Tumors

Phase 1a/1b GTB-5550 in Advanced Solid Tumors

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

MYTHIC

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

A Study of HS-20110 in Participants With Advanced Solid Tumors

PARTHENON

A Study of HDM2024 in Participants With Advanced Solid Tumors

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

TMB-H

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

ICE COMPRESS

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

CLINCH

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

A Study of BG-C477 in Participants With Advanced Solid Tumors

ANTARES

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

SNV1521 in Participants With Advanced Solid Tumors

Retinoblastoma Phase II Expanded Access Clinical Trial

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Study of TRX-920 for Patients With Advanced Solid Tumors

ASCENT

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy